Business
AXIM® Biotech Expands Advisory Board With Oncology Specialist and Medicinal Cannabis Leading Expert – Dr. Donald Abrams
AXIM® Biotech Expands Advisory Board With Oncology Specialist and Medicinal Cannabis Leading Expert – Dr. Donald Abrams.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco.\n\n \n \n \n \n \n \n \n \n \n \n \n Dr. Donald Abrams, professor and hematology-oncology specialist, joins AXIM® Biotech’s Board of Advisors.\n \n \n \n \n \n \n \n \n\n A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/b1dcfc25-e7da-4d33-a468-99714b731345 “We are very pleased and honored to have Dr. Abrams join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “In addition to being an oncology specialist who was one of the original clinicians to recognize and define many early AIDS-related conditions, Dr. Abrams has authoritative expertise in medicinal cannabis research and clinical trials. Working with AXIM management and other members of our advisory board, Dr. Abrams will further enhance the intellectual rigor of our research and help better address patient needs with cannabinoid based pharmaceutical solutions.” “I am excited to be joining the board as I am impressed with AXIM’s innovative technology aiming to make cannabis-based medicines available to a larger population of patients through its novel delivery systems,” said Dr. Abrams. Dr. Abrams has long been involved in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997, Dr. Abrams received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently, he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. Dr. Abrams completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery...